Lyell Immunopharma, Inc.LYELNASDAQ
LOADING
|||
Switch Symbol:
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
20.97%
↑ 174% above average
Average (22q)
-28.42%
Historical baseline
Range
High:76.02%
Low:-302.98%
Volatility
-1333.6%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 20.97% |
| Q2 2025 | 17.83% |
| Q1 2025 | 71.48% |
| Q4 2024 | -298.27% |
| Q3 2024 | 1.99% |
| Q2 2024 | 7.28% |
| Q1 2024 | 7.11% |
| Q4 2023 | 1.23% |
| Q3 2023 | 8.03% |
| Q2 2023 | -2.20% |
| Q1 2023 | -302.98% |
| Q4 2022 | 76.02% |
| Q3 2022 | -80.08% |
| Q2 2022 | 47.62% |
| Q1 2022 | -46.26% |
| Q4 2021 | 1.68% |
| Q3 2021 | 21.60% |
| Q2 2021 | -36.47% |
| Q1 2021 | -16.25% |
| Q4 2020 | -7.28% |
| Q3 2020 | 64.08% |
| Q2 2020 | -210.77% |
| Q1 2020 | 0.00% |